The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 316-322 , March 2010

Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease

  • Farzin Beygui, MD, PhD

      Affiliations

    • Cardiology Department, Pitié-Salpêtrière University Hospital, Paris, France
    • INSERM U 937, Pitié-Salpêtrière University Hospital, Paris, France
    • Corresponding Author InformationReprint requests: Farzin Beygui, MD, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. Telephone: 33-1-42163011. Fax: 33-1-42163034
    • ,
  • Shaida Varnous, MD

      Affiliations

    • Cardiac and Thoracic Surgery Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Gilles Montalescot, MD, PhD

      Affiliations

    • Cardiology Department, Pitié-Salpêtrière University Hospital, Paris, France
    • INSERM U 937, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Flor Fernandez, MD

      Affiliations

    • Cardiac and Thoracic Surgery Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Jean-Philippe Collet, MD, PhD

      Affiliations

    • Cardiology Department, Pitié-Salpêtrière University Hospital, Paris, France
    • INSERM U 937, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Pascal Leprince, MD, PhD

      Affiliations

    • Cardiac and Thoracic Surgery Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Claude Le Feuvre, MD

      Affiliations

    • Cardiology Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Alain Pavie, MD

      Affiliations

    • Cardiac and Thoracic Surgery Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Michel Komajda, MD

      Affiliations

    • Cardiology Department, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Jean-Philippe Metzger, MD

      Affiliations

    • INSERM U 937, Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Iradj Gandjbakhch, MD

      Affiliations

    • Cardiac and Thoracic Surgery Department, Pitié-Salpêtrière University Hospital, Paris, France

References 

  1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report—2006. J Heart Lung Transplant. 2006;25:869–879
  2. Syeda B, Roedler S, Schukro C, et al. Transplant coronary artery disease: incidence, progression and interventional revascularization. Int J Cardiol. 2005;104:269–274
  3. Aranda JM, Pauly DF, Kerensky RA, et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy (One center's experience). J Heart Lung Transplant. 2002;21:860–866
  4. Schnetzler B, Drobinski G, Dorent R, et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant. 2000;19:557–565
  5. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol. 2004;43:1973–1981
  6. Simpson L, Lee EK, Hott BJ, et al. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant. 2005;24:1211–1217
  7. Bader FM, Kfoury AG, Gilbert EM, et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant. 2006;25:298–301
  8. Jonas M, Fang JC, Wang JC, et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol. 2006;48:453–461
  9. Tanaka K, Li H, Curran PJ, et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol. 2006;97:1192–1197
  10. Jain SP, Ramee SR, White CJ, et al. Coronary stenting in cardiac allograft vasculopathy. J Am Coll Cardiol. 1998;32:1636–1640
  11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  12. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537–1545
  13. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44–52
  14. Rahmani M, Cruz RP, Granville DJ, et al. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801–815
  15. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700
  16. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108:48–53
  17. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858
  18. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol. 2004;44:1386–1392
  19. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006;47:1522–1529
  20. Wellnhofer E, Hiemann NE, Hug J, et al. A decade of percutaneous coronary interventions in cardiac transplant recipients: a monocentric study in 160 patients. J Heart Lung Transplant. 2008;27:17–25
  21. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428–1436
  22. Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002;105:2986–2991
  23. Erinc K, Yamani MH, Starling RC, et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24:1033–1038
  24. Braith RW, Mills RM, Wilcox CS, et al. High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol. 2003;41:426–432
  25. Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant. 1992;11:1194–1199
  26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  27. Barbir M, Lazem F, Banner N, et al. The prognostic significance of non-invasive cardiac tests in heart transplant recipients. Eur Heart J. 1997;18:692–696

PII: S1053-2498(09)00708-6

doi: 10.1016/j.healun.2009.08.020

The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 316-322 , March 2010

Article Tools

* Image Usage & Resolution